|
|
|
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA
Meeting Notice
Amended
Changes in the Location, Agenda and Procedure
portions of the meeting.
| Center | Date | Time | Location |
|---|---|---|---|
| CDER | June 10, 2004 | 8 a.m. - 5:30 p.m. | Food and Drug
Administration |
Agenda:
The committee will discuss the possible removal of the essential use designation
of albuterol under 21 CFR 2.125.
Background material and meeting information will become available no later than the day before the meeting (Simply select the appropriate committee link).
Procedure:
Interested persons may present data, information, or views, orally or in writing,
on issues pending before the committee. Written submissions may be made to the
contact person by May 24, 2004. Oral presentations from the public will be scheduled
between approximately 11 a.m. and 1 p.m. Time allotted for each presentation
may be limited. Those desiring to make formal oral presentations should notify
the contact person before May 24, 2004, and submit a brief statement of the
general nature of the evidence or arguments they wish to present, the names
and addresses of proposed participants, and an indication of the approximate
time requested to make their presentation. Persons attending FDA's advisory
committee meetings are advised that the agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the public at its advisory committee meetings
and will make every effort to accommodate persons with physical disabilities
or special needs. If you require special accommodations due to a disability,
please contact Shalini Jain at least 7 days in advance of the meeting.
Contact Person:
Shalini Jain, Center for Drug Evaluation and Research (HFD-21), Food and Drug
Administration, 5600 Fishers Lane (for express delivery: 5630 Fishers Lane,
Rm. 1093), Rockville, MD 20857, 301-827-7001, or e-mail: jains@cder.fda.gov,
or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in
the Washington, DC area), code 3014512545. Please call the Information Line
for up-to-date information on this meeting.
[ Full FR Notice ]